N N Filatov

N N Filatov

Auto-generated profile, based on publicly available information

N N Filatov

ФГБНУ «Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова»; ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2000 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
KBKristine M. Bisgard
Kristine M. Bisgard
PRPhilip Rhodes
Philip Rhodes
IHIain R. B. Hardy
Iain R. B. Hardy
ILIrina L. Litkina
Irina L. Litkina
NFNikolai N. Filatov
Nikolai N. Filatov
MWMelinda Wharton
Melinda Wharton
Prior to the completion of this and other studies, low effectiveness of diphtheria toxoid-containing vaccine was suspected to be a major contributing

15 May 2021 in Problems of Virology
Verified
Journal Article
Open access
PDF file
TST. V. Solomay
T. V. Solomay
TSTatiana A. Semenenko
Tatiana A. Semenenko
NFN. N. Filatov
N. N. Filatov
SVS. L. Vedunova
S. L. Vedunova
VLV. F. Lavrov
V. F. Lavrov
EFEvgeny Faizuloev
Evgeny Faizuloev
Introduction. Immunodeficiency underlying the development of severe forms of new coronavirus infection may be the result of mixed infection with SARS-CoV-2 and other pathogens, including Epstein–Barr virus (EBV).The aim is to study the prevalence and epidemiological features of co-infection with SARS-CoV-2 and EBV. Material and methods. A cross-sectional randomized study was conducted in Moscow region from March to May 2020. Two groups were examined for EBV-markers: hospital patients (n = 95) treated for SARS-CoV-2 infection and blood donors (n = 92).Results. With equal EBV prevalence the detection of active infection markers in donors (10.9%) was noticeably lower than in SARS-CoV-2 patients (80%). Significant differences in this indicator were also found when patients from subgroups with interstitial pneumonia with the presence (96.6%) and absence (97.2%) of SARS-CoV-2 in the nasopharyngeal smear were compared with the subgroup of patients with mild COVID-19 (43.3%). The average IgG VCA and IgG EBNA positivity coefficients in donor group were higher than in patient group (p 0.05). Patients with active EBV infection markers were significantly more likely to have pneumonia, exceeding the reference values of ALT and the relative number of monocytes (odds ratio – 23.6; 3.5; 9.7, respectively).Discussion. The present study examined the incidence and analyzed epidemiological features of active EBV infection in patients with COVID-19.Conclusion. A significantly higher rate of detection of active EBV infection markers in hospital patients indicates a combined participation SARS-CoV-2 and EBV in the development of interstitial pneumonia. Low levels of specific IgG EBV serve as predictors of EBV reactivation. Exceeding the reference values of ALT and the relative number of monocytes in patients should serve as a reason for examination for active EBV infection markers.

30 September 2020 in CHILDREN INFECTIONS
Verified
Journal Article
Open access
PDF file
TST. V. Solomay
T. V. Solomay
TSTatiana A. Semenenko
Tatiana A. Semenenko
NFN. N. Filatov
N. N. Filatov
KKK. B. Kolbutova
K. B. Kolbutova
DOD. Yu. Oleinikova
D. Yu. Oleinikova
ДОД. Ю. Олейникова
Д. Ю. Олейникова
Роль детей и взрослых как резервуара возбудителей в период сезонного подъема заболеваемости инфекциями верхних дыхательных путей

1 January 2020 in Immunologiya
Verified
Journal Article
Closed access
TST.V. Solomay
T.V. Solomay
IAInterregional Department No 1 of the Federal Medico-biological Agency
Interregional Department No 1 of the Federal Medico-biological Agency
TSTatiana A. Semenenko
Tatiana A. Semenenko
NFN.N. Filatov
N.N. Filatov
МKМikhail Petrovich Kostinov
Мikhail Petrovich Kostinov
NANational Research Center Institute of Immunology of the Federal Medico-biological Agency
National Research Center Institute of Immunology of the Federal Medico-biological Agency

1 September 1997
Verified
Journal Article
Closed access
NBN I Briko
N I Briko
NBN V Bovin
N V Bovin
BSB I Shevelev
B I Shevelev
LDL O Dynga
L O Dynga
EBE I Blinnikova
E I Blinnikova
NFN N Filatov
N N Filatov

21 October 2003
Verified
Journal Article
Closed access
NBN I Briko
N I Briko
NFNikolay Filatov
Nikolay Filatov
MZM V Zhuravlev
M V Zhuravlev
ILI N Lytkina
I N Lytkina
EEE B Ezhlova
E B Ezhlova
NMN A Malyshev
N A Malyshev